Results of the ASPIRE trial for MM: the addition of carfilzomib - 101793

Spotlight
Video

Results of the ASPIRE trial for MM: the addition of carfilzomib

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA presented exciting results from the ASPIRE trial (NCT01080391) for relapsed multiple myeloma (MM), testing the addition of the proteasome inhibitor carfilzomib to lenalidomide and dexamethasone therapy. Speaking from the meeting, Greg Friberg, MD, of Amgen Inc., Thousand Oaks, CA, discusses the positive follow-up data presented on patient outcomes.
Shared By : VJHemOnc
Posted on : 01/03/18
Added : 12 months ago
Category : Multiple Myeloma